The European Union on May 6 backed a U.S. proposal to discuss waiving patent protections for Covid-19 vaccines, but drugmakers and some other governments opposed the idea, saying it would not solve global inoculation shortages.
Manufacturing capacity and ingredients shortages are the main bottlenecks to expanding Covid-19 vaccine production, several global drug groups said on March 9, not patents that some critics are demanding be removed.
BioSpace looks at some of the top stories from Day 2 of the virtual JP Morgan Annual Healthcare Conference.
The U.S. Food and Drug Administration accepted for priority review a Biologics License Application (BLA) for Merck’s 15-valent pneumococcal conjugate vaccine V114.
Shares of Amarin Corporation were down more than 70 percent in trading after a judge ruled that generic companies can go ahead and seek approval of generic versions of the drug manufacturer’s heart disease drug Vascepa.
Danish drugmaker Novo Nordisk beat first-quarter 2019 operating profit forecasts, helped by higher sales of the company’s biggest new drug hope, a treatment for type 2 diabetes.
The loss of patent protection on two drugs is forcing Gilead Sciences to terminate about 20 percent of the company’s sales team, according to reports.
Australia’s competition watchdog said the High Court dismissed its special leave application to appeal a court’s decision on whether Pfizer Inc.’s local unit used the company’s market power to limit competition for the cholesterol-lowering drug Lipitor.
U.S. regulators approved expanded use of Roche’s drug Hemlibra to include almost all patients with hemophilia A.